Matthew Koslow, MD
Internal Medicine · Denver, CONPI 1487018750
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,478 of the $20,516 with a category attached, or 94.9%. Boehringer Ingelheim accounts for 96.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $7,164 and has fallen 94.7% since, to $383 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $820.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$20K
- United Therapeutics Corporation$494
- Regeneron Healthcare Solutions, Inc.$102
- Gilead$91
- Actelion Pharmaceuticals US, Inc.$49
- AstraZeneca$34
- plus $15 from 1 others
Across 2 payments — averaging $80,632 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$161K
What the payments were for
- Speaking & faculty fees$19,47895%
- Food & beverage$1,0385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $19,732 |
| United Therapeutics Corporation | 8 | $494 |
| Regeneron Healthcare Solutions, Inc. | 1 | $102 |
| Gilead | 5 | $91 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| AstraZeneca | 2 | $34 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,516 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 97 | $1,242,336 |
| Pirfenidone | 65 | $142,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $49,864 |
| Spiriva HandihalerTiotropium Bromide | 38 | $21,378 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,878 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $11,736 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,950 |
| Sirolimus | 13 | $9,777 |
| DuleraMometasone/Formoterol | 19 | $8,204 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,555 |
| Mycophenolate Mofetil | 74 | $6,863 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,624 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $784 |
| Azelastine Hcl | 15 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $19,732 | $1,242,33697 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $15 | $83,528132 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $34 | $28,45360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Denver
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Katherine TsaiDenver$15K
- Saurabh MangalikDenver$14K
- David MellmanDenver$12K
- Cara DawsonDenver$11K
- Jason HenryDenver$10K
- Emily AaronDenver$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.